MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, UPB had -$224,314K decrease in cash & cash equivalents over the period. -$133,440K in free cash flow.

Cash Flow Overview

Change in Cash
-$224,314K
Free Cash flow
-$133,440K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of short-term investm...
    • Stock-based compensation expense
    • Accrued expenses and other curre...
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Prepaid expenses and other asset...
    • Net amortization of premiums and...
    • Others

Cash Flow
2025-12-31
Net loss
-143,443
Depreciation and amortization expense
188
Stock-based compensation expense
10,332
Change in fair value of preferred stock tranche right liability
0
Net amortization of premiums and accretion of discounts on short-term investments
1,502
Non-cash lease expense
561
Accounts receivable
55
Prepaid expenses and other assets
1,524
Accounts payable
-1,281
Accrued expenses and other current liabilities
4,014
Operating lease liabilities
-565
Net cash used in operating activities
-133,275
Purchases of short-term investments
385,878
Maturities of short-term investments
292,563
Purchases of equipment
165
Net cash used in investing activities
-93,480
Proceeds from the issuance of series b redeemable convertible preferred stock, net of issuance costs paid
0
Proceeds from initial public offering, net of underwriters discounts and commissions
0
Payments of initial public offering costs
34
Proceeds from exercises of stock options
2,279
Proceeds from issuance of common stock under employee stock purchase plan
196
Net cash provided by financing activities
2,441
Net increase (decrease) in cash, cash equivalents and restricted cash
-224,314
Cash, cash equivalents and restricted cash at beginning of period
326,086
Cash, cash equivalents and restricted cash at end of period
101,772
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from exercisesof stock options$2,279K Proceeds from issuance ofcommon stock under...$196K Net cash provided byfinancing activities$2,441K Canceled cashflow$34K Net increase(decrease) in cash, cash...-$224,314K Canceled cashflow$2,441K Stock-based compensationexpense$10,332K Accrued expenses andother current...$4,014K Non-cash lease expense$561K Depreciation andamortization expense$188K Maturities of short-terminvestments$292,563K Payments of initialpublic offering costs$34K Net cash used inoperating activities-$133,275K Net cash used ininvesting activities-$93,480K Canceled cashflow$15,095K Canceled cashflow$292,563K Net loss-$143,443K Purchases of short-terminvestments$385,878K Prepaid expenses andother assets$1,524K Net amortization ofpremiums and accretion of...$1,502K Accounts payable-$1,281K Operating leaseliabilities-$565K Accounts receivable$55K Purchases of equipment$165K

Upstream Bio, Inc. (UPB)

Upstream Bio, Inc. (UPB)